Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 2897-2908

  von Minckwitz, Gunter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bisphosphonates; Bone metastasis; Chemotherapy; CNS metastasis; Endocrine therapy; Evidence based recommendations; Guideline; Metastatic breast cancer; Trastuzumab; Visceral metastasis

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FADROZOLE; FLUOROURACIL; FORMESTANE; FULVESTRANT; GEMCITABINE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ARTHRALGIA; ARTICLE; BONE MARROW CANCER; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EFFUSION; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MONITORING; MYOCARDIAL DISEASE; NAUSEA; OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SIDE EFFECT; SOFT TISSUE METASTASIS; SWEATING; SYSTEMIC THERAPY; THROMBOEMBOLISM; VAGINA BLEEDING; VISCERAL METASTASIS; VOMITING; WEIGHT GAIN;

ANTIBODIES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; FEMALE; FORECASTING; HUMANS;

EID: 33750501586     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.06.033     Document Type: Article

References (49)

1. Levels of evidence and grades of recommendation. Centre for evidence-based medicine. http://www.cebm.net/levels_of_evidence.asp; 2001.
2. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16 (1998) 3439-3460
3. Stockler M., Wilcken N.R., Ghersi D., and Simes R.J. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26 (2000) 151-168
4. Hayes D.F. Prognostic and predictive factors for breast cancer: Translating technology to oncology. J Clin Oncol 23 (2005) 1596-1597
5. Fehm T., Jager W., Kramer S., et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24 (2004) 1987-1992
6. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 (2005) 1420-1430
7. Robertson J.F.R., Pearson D., Price M.R., et al. Objective measurement of therapeutic response in breast cancer using tumor markers. Br J Cancer 64 (1991) 757-763
8. Osborne C.K., Schiff R., Arpino G., et al. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 14 (2005) 458-465
9. Bonneterre J., Thurlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
10. Paridaens R., Dirix L., Lohrisch C., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14 (2003) 1391-1398
11. Crump M., Sawka C.A., DeBoer G., et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44 (1997) 201-210
12. Sledge Jr. G.W., Hu P., Falkson G., Tormey D., and Abeloff M. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 18 (2000) 262-266
13. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
14. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22 No 14S (July 15 Supplement): 510.
15. O'Brien M.E., Wigler N., Inbar M., et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
16. Nabholtz J.M., Senn H.J., Bezwoda W.R., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17 (1999) 1413-1424
17. Ghersi D, Wilcken N, Simes J, Donoghue E. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (3):CD003366; 2003.
18. Reichardt P., Von Minckwitz G., Thuss-Patience P.C., et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14 (2003) 1227-1233
19. Keller A.M., Mennel R.G., Georgoulias V.A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 (2004) 3893-3901
20. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
21. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
22. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
23. Baselga J., Carbonell X., Castaneda-Soto N.J., et al. Phase II study of efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23 (2005) 2162-2171
24. Bell R., Verma S., Untch M., Cameron D., and Smith I. Maximizing clinical benefit with trastuzumab. Semin Oncol 31 Suppl 10 (2004) 35-44
25. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. Ann Oncol 14 (2003) 1697-1704
26. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
27. Miller K. A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3 (2003) 421-422
28. Navo M.A., Phan J., Vaughan C., et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22 (2004) 671-677
29. Gerber B., Muller H., Reimer T., et al. Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat 79 (2003) 265-276
30. Piao B.K., Wang Y.X., Xie G.R., et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24 (2004) 303-309
31. Saintot M., Mathiau-Daude H., Astre C., et al. Oxidant-antioxidant status in relation to survival among breast cancer patients. Int J Cancer 97 (2002) 574-579
32. Courneya K.S., Mackey J.R., Bell G.J., et al. J Clin Oncol 21 (2003) 1660-1668
33. Brown J.E., and Coleman R.E. Metastatic bone disease: developing strategies to optimize management. Am J Cancer 2 (2003) 269-281
34. Fourney D.R., and Gokaslan Z.L. Thoracolumbar spine: surgical treatment of metastatic disease. Curr Opin Orthop 14 (2003) 144-152
35. Fourney D.R., Schomer D.F., Nader R., et al. Percutaneos and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98 (2003) 21-30
36. Roque M, Martinez MJ, Alonso-Coello P, et al. Radioisotopes for metastatic bone pain (Cochrane review). In: The Cochrane Library Issue 3. Chichester, UK: John Wiley & Son, Ltd. (Cochrane Database Syst Rev 2003: CD003347), 2004.
37. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16 (1998) 2038-2044
38. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
39. Helmberger T., Holzknecht N., Schopf, et al. Radiofrequency ablation of liver metastases. Technique and initial results. Radiologe 41 (2001) 69-76
40. Raab R., Nussbaum K.T., Behrend M., et al. Liver metastases of breast cancer: results of liver resection. Anticancer Res 18 (1998) 2231-2233
41. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. (1): CD002916; 2004.
42. Link K.H., Roitman M., Holtappels M., et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 12 (2005) 865-872
43. Frankel K.M. Malignant pericardial effusions. Chest 126 (2004) 1713
44. Chavez-Macgregor M., Aviles-Salas A., Green D., et al. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 11 (2005) 5340-5396
45. Langer C.J., and Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 (2005) 6207-6219
46. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 17 (1998) 1485-1498
47. Andrews D.W., Scott C., Sperduto P.W., et al. Phase III randomized trial comparing whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Results of the RTOG 9508 trial. Lancet 363 (2004) 1665-1673
48. Glantz M.J., Jaeckle K.A., Chamberlain M.C., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meninigitis from solid tumors. Clin Cancer Res 5 (1999) 3394-3402
49. Chamberlain M.C. Neoplastic meningitis. J Clin Oncol 23 (2005) 3605-3613